Target intelligence / Profile preview

Large ribosomal subunit protein uL22 (uL22)

Target
uL22
Molecular classification
Ribosomal protein, Structural constituent of ribosome
01

Overview

Large ribosomal subunit protein uL22 is a highly conserved structural component of the bacterial 50S ribosomal subunit, encoded by the rplV gene. It plays a critical role in ribosome assembly by interacting with the 23S rRNA and other ribosomal proteins, facilitates the folding of rRNA, and forms an important part of the ribosomal exit tunnel through which newly synthesized polypeptides emerge. uL22 is essential for protein synthesis and is a key target for several antibiotic classes, primarily macrolides such as erythromycin. Mutations in uL22 can cause resistance to these antibiotics by altering tunnel structure and thus diminishing drug binding. Although not a human therapeutic target, uL22 is highly relevant in the context of bacterial infection and antibiotic therapy.

Other names
50S ribosomal protein L22Large ribosomal subunit protein uL22rplV
02

Mechanism of action

Drugs bind to the ribosomal exit tunnel (lined in part by uL22), blocking passage of the nascent polypeptide and inhibiting protein synthesis. Mutations in uL22 alter tunnel conformation and can reduce drug binding, leading to resistance.

03

Biological functions

rRNA bindingStructural constituent of ribosomeFacilitates ribosome biogenesis and folding of rRNA during assemblyInvolved in mRNA-directed protein synthesis (translation)
04

Disease associations

Infection (especially bacterial, as it is a major bacterial protein target for antibiotics)Antibiotic resistance (mutations in uL22 confer resistance to macrolide antibiotics, e.g., erythromycin)
05

Safety considerations

Antibiotic resistance in bacteria with mutated uL22 reduces efficacy of macrolide treatment, complicating infection managementNo specific therapeutic challenge when targeting uL22 directly (it is not a target in humans, but in bacterial pathogens)
06

Interacting drugs

Erythromycin (macrolide antibiotic)

2 more in the full profile.

Beyond the preview

Go deeper on Large ribosomal subunit protein uL22 (uL22).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large ribosomal subunit protein uL22 (uL22).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call